Spanish VCs back ForMune with €4.4m
Venture capital firms Inveready and Caja Navarra, alongside public company Navarra Development Society (Sodena), have supported the spinout of biotech firm ForMune from parent company Digna Biotech with a capital commitment of €4.4m over the next three years.
The investment is in line with Caja Navarra and Sodena's focus on the promotion of biotechnology in Navarre.
Company
ForMune will work on the development of molecules for licensing to pharmaceutical companies and marketing. The company will initially focus on the development of two products: the first is a therapy for the treatment of neck uterine cancer, while the second targets liver infections of the Hepatitis B virus.
People
Jose Maria Echarri is CEO of Inveready.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds








